scholarly journals Independent role of interleukin interleukin-6 and interleukin-8 in the etiology of transfusion reactions to platelet concentrates in children

2018 ◽  
Vol 75 (4) ◽  
pp. 390-397 ◽  
Author(s):  
Olivera Serbic-Nonkovic ◽  
Milos Kuzmanovic ◽  
Maja Zivotic ◽  
Svetlana Zunic ◽  
Dragana Jovicic-Gojkov ◽  
...  
Keyword(s):  
Interleukin 6 ◽  
Pediatric Population ◽  
Buffy Coat ◽  
Transfusion Reaction ◽  
Platelet Concentrates ◽  
Leukocyte Antigen ◽  
Platelet Antibodies ◽  
Platelet Antigen ◽  
Transfusion Reactions

Background/Aim. Transfusion reaction is an adverse event which manifests during or after administration of blood components to the patient. We aimed to show less known aspects of most common transfusion reactions (allergic and febrile non-hemolytic transfusion reactions ? FNHTR) in the pediatric population at the platelet concentrates. The aim of this study was to determine the role of the accumulated cytokines interleukin-6 (IL-6), interlekin- 8 (IL-8) and presence of anti-platelet antibodies in the etiology of transfusion reaction in children. Methods. The study included 239 pediatric patients, who received platelet concentrates. Data of reported transfusion reaction were collected and evaluated prospectively. The levels of IL-6 and IL-8 were determined using an immunoassay. Antihuman leukocyte antigen antibodies (anti-HLA) and antihuman platelet antigen antibodies (anti-HPA) were identified by Luminex flow cytometry. Results. Toral of 70 transfusion reactions were recorded 52 patients. Allergic reactions occurred in most of the cases (74.3%), followed by FNHTR (17.1%). Platelets derived from buffy coat caused the majority of reactions (73.5%). Patients with infection after platelet transfusion with FNHTR had the highest levels of IL-6, 483.30 ? 1,041.79 pg/mL (p = 0.020). Respectively, the febrile patients had IL-6, 302.52 ? 720.04 pg/mL (p = 0.004). The level of IL-8 in platelet units that caused transfusion reactions was 95.66 ? 319.10 pg/mL, which was significantly higher (p = 0.001) compared to the control platelet units. Conclusion. The predominant etiologic mechanism for FNHTR in our study was leukocyte derived cytokine accumulation during storage. Etiopathogenesis of FNHTR induced by IL-6 and IL- 8 presented differently. We concluded that significant factors in the etiology of FNHTR by IL-6 were the factors related to the pediatric patient (infection, inflammation).

Generation of procoagulant collagen- and thrombin-activated platelets in platelet concentrates derived from buffy coat: the role of processing, pathogen inactivation, and storage

Transfusion ◽  
2018 ◽  
Vol 58 (10) ◽  
pp. 2395-2406 ◽  
Author(s):  
Debora Bertaggia Calderara ◽  
David Crettaz ◽  
Alessandro Aliotta ◽  
Stefano Barelli ◽  
Jean-Daniel Tissot ◽  
...  
Keyword(s):  
Buffy Coat ◽  
Pathogen Inactivation ◽  
Platelet Concentrates ◽  
Activated Platelets ◽  
And Storage

scholarly journals Recurrent Focal Segmental Glomerulosclerosis in Renal Allograft Recipients: Role of Human Leukocyte Antigen Mismatching and Other Clinical Variables

2011 ◽  
Vol 2011 ◽  
pp. 1-9 ◽  
Author(s):  
Shimi Sharief ◽  
Shefali Mahesh ◽  
Marcela Del Rio ◽  
Vivian Telis ◽  
Robert P. Woroniecki
Keyword(s):  
Focal Segmental Glomerulosclerosis ◽  
Pediatric Population ◽  
Surrogate Marker ◽  
Human Leukocyte ◽  
Leukocyte Antigen ◽  
Clinical Variables ◽  
Segmental Glomerulosclerosis ◽  
Hla Compatibility

Recurrence of focal segmental glomerulosclerosis (FSGS) after renal transplantation impacts long-term graft survival and limits access to transplantation. We hypothesized that HLA donor/recipient matching could be used as a surrogate marker of recurrence. In a retrospective study of 42 pediatric and 77 adult subjects with primary FSGS, transplanted from 1990 to 2007 at a single center, we analyzed the degree of donor/recipient HLA compatibility and other clinical variables associated with FSGS recurrence. There were total of 131 allografts for primary FSGS (11 subjects were transplanted twice, and 1 had a third allograft) with 20 cases of FSGS recurrence (17 children) in the primary allograft, and two children who had FSGS recurrence in the second allograft. Fifty-two subjects (40%) were African American, and 66 (50%) Caucasians. Recurrent FSGS and controls were not different for age at transplant, gender, donor source, acute/chronic rejection episodes, and HLA matches. Recurrent FSGS was not associated with HLA mismatches; power equals 83%. Immunosuppressive regimen had no effect on recurrence of FSGS, . Recurrent FSGS is not associated with HLA mismatching, acute cellular or vascular rejection, and occurs primarily in the pediatric population.

The Role of the Plasma from Platelet Concentrates in Transfusion Reactions

1994 ◽  
Vol 331 (10) ◽  
pp. 625-628 ◽  
Author(s):  
Nancy M. Heddle ◽  
Luba Klama ◽  
Joel Singer ◽  
Carl Richards ◽  
Paul Fedak ◽  
...  
Keyword(s):  
Platelet Concentrates ◽  
Transfusion Reactions

Post-transfusion purpura due to anti HPA–1a antibodies – a retrospective case report

2021 ◽  
Vol 56 (4) ◽  
pp. 1-6
Author(s):  
Bożena Andrys ◽  
Magdalena Polcyn-Adamczak
Keyword(s):  
Human Leukocyte ◽  
Hla Class I ◽  
Intravenous Immunoglobulins ◽  
Retrospective Case ◽  
Leukocyte Antigen ◽  
Platelet Antibodies ◽  
Platelet Antigen ◽  
Skin Symptoms ◽  
Human Platelet Antigen ◽  
Life Threatening

Post-transfusion purpura is a life-threatening adverse reaction associated with a reduction in platelet counts below 10 x 109/L and bleeding. It usually occurs in women who, due to their pregnancies, have developed antibodies directed against human platelet antigen (HPA), most often anti-HPA 1a. The case described by us concerned an 83-year-old woman who received two units of red blood cells (RBC) due to severe secondary anemia. Seven days after the transfusion, she developed skin symptoms of thrombocytopenic diathesis, gastrointestinal bleeding, and a reduced number of platelets (3 x 109/L), and the patient’s serum (genotype HPA-1b/1b) was positive for anti-platelet antibodies with HPA-1a specificity and directed against human leukocyte antigen (HLA) class I and class II antibodies, unresponsive to the lymphocytotoxic test. Prompt diagnosis by our transfusion medicine consultant and the initiation of treatment with intravenous immunoglobulins certainly shortened the duration of thrombocytopenia and bleeding, and possibly also saved the patient’s life.

Effectiveness of Splenectomy and Platelet Autoantibodies.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 3878-3878
Author(s):  
Anna Sikorska ◽  
Krystyna Maslanka ◽  
Andrzej Misiak ◽  
Lech Konopka ◽  
Barbara Zupanska
Keyword(s):  
Small Groups ◽  
Response Rate ◽  
Initial Response ◽  
Individual Response ◽  
Platelet Antibodies ◽  
Platelet Antigen ◽  
Before And After ◽  
Platelet Autoantibodies

Abstract The role of the spleen in pathophysiology of Idiopatic Thrombocytopenic Purpura (ITP) remains incompletely defined. Splenectomy has a fairly favourable initial response rate of 60% to 80%, and the longer the follow-up, the lower the success rate. As yet, there is no consistently effective method of predicting an individual response to splenectomy. So far not many observations have been published and if so, they were based on very small groups of ITP. The aim of this work was to evaluate the response to splenectomy in 151 patients with ITP in relation to the detection of platelet autoantibodies. 151 ITP patients before and after splenectomy were observed for a period of 16 years. Autoantibodies were examined by the platelet immunofluoresce test (PIFT) and/or by the monoclonal antibody immunobilization of platelet antigen (MAIPA) assay, sometimes in addition the HPA genotyping was performed using the PCR. The response to splenectomy was regarded to be very good if platelet count was >150 G/l during at least 6 months follow-up. However, some patients were followed-up even for 15 years. Overall, platelet antibodies were detected in 34.3% (52/151) of patients. In 76% out of 52 patients the antibodies were detected by PIFT, in 63% by MAIPA; both tests were positive in 27% of patients. Most antibodies reacted with GPIIbIIIa. Splenectomy was effective in 57% (30/52) of patients with antibodies and in 75.8% (75/99) of patients without detectable antibodies (p<0.01). In the effective splenectomy and antibodies group, in 23 patients the antibodies were examined during a follow-up and in 10 of them (43.5%) were not detected. In the uneffective splenectomy group only in 4 out of 18 (22.2%) examined patients the antibodies were not found. The differences between these groups were not significant. Our data show that autoantibody platelet examination is not very helpful for predicting the effectiveness of splenectomy.

The Role of Plasma from Platelet Concentrates in Transfusion Reactions

1995 ◽  
Vol 39 (2) ◽  
pp. 135
Author(s):  
NANCY M. HEDDLE ◽  
LUBA KLAMA ◽  
JOEL SINGER ◽  
CARL RICHARDS ◽  
PAUL FEDAK ◽  
...  
Keyword(s):  
Platelet Concentrates ◽  
Transfusion Reactions

Platelet transfusion reactions do not occur more often in recipients transfused with apheresis versus buffy coat platelet concentrates

Transfusion ◽  
2016 ◽  
Vol 56 (12) ◽  
pp. 3144-3146 ◽  
Author(s):  
Christine Cserti-Gazdewich ◽  
Alioska Escorcia ◽  
Jacob Pendergrast ◽  
Lani Lieberman ◽  
Robert Skeate ◽  
...  
Keyword(s):  
Platelet Transfusion ◽  
Buffy Coat ◽  
Platelet Concentrates ◽  
Transfusion Reactions

A multicenter randomized study of the efficacy of transfusions with platelets stored in platelet additive solution II versus plasma

Blood ◽  
2006 ◽  
Vol 108 (9) ◽  
pp. 3210-3215 ◽  
Author(s):  
Jean-Louis H. Kerkhoffs ◽  
Jeroen C. Eikenboom ◽  
Martin S. Schipperus ◽  
Rinie J. van Wordragen-Vlaswinkel ◽  
Ronald Brand ◽  
...  
Keyword(s):  
Multivariate Analysis ◽  
Clinical Efficacy ◽  
Randomized Study ◽  
Buffy Coat ◽  
Bleeding Complications ◽  
Platelet Concentrates ◽  
Storage Medium ◽  
Clinical Complications ◽  
Additive Solution ◽  
Transfusion Reactions

Abstract Randomized studies testing the clinical efficacy of platelet additive solutions (PASs) for storage of platelets are scarce and often biased by patient selection. We conducted a multicenter, randomized study to investigate clinical efficacy of platelets stored in PAS II versus plasma, also including patients with clinical complications associated with increased platelet consumption. A total of 168 evaluable patients received pooled buffy coat–derived platelet concentrates (PCs) suspended in either plasma (n = 354) or PAS II (n = 411) stored up to 5 days. Both univariate as well as multivariate analysis showed a significant effect of used storage medium in regard to 1- and 24-hour count increments and corrected count increments, in favor of plasma PCs. However, there were no significant differences between the groups regarding bleeding complications and transfusion interval. Adverse transfusion reactions occurred significantly less after transfusions with PAS II PCs (P = .04). Multivariate analysis showed no significant effect of the used storage medium on the incidence of 1- and 24-hour transfusion failure. We showed safety and efficacy of PAS II PCs in intensively treated patients; however, plasma PCs show superior increments.

scholarly journals The Role of Molecular Typing for DQ2 and DQ8 Alleles Using Polymerase Chain Reaction Amplification in Children with Autoimmune Conditions

2020 ◽  
Vol 71 (6) ◽  
pp. 212-221
Author(s):  
Oana Belei ◽  
Andreea Dobrescu ◽  
Emil Radu Iacob ◽  
Daniela Iacob ◽  
Elena Amaricai ◽  
...  
Keyword(s):  
Polymerase Chain Reaction Amplification ◽  
Pediatric Population ◽  
Human Leukocyte ◽  
Intestinal Biopsy ◽  
Leukocyte Antigen ◽  
High Prevalence ◽  
Autoimmune Conditions ◽  
Reaction Amplification ◽  
Serologic Screening

The aim was to determine the prevalence of celiac disease (CD) in a pediatric population with juvenile idiopathic arthritis (JIA) and autoimmune hepatitis (AIH) compared to controls and to evaluate the clinical forms and human leukocyte antigen (HLA) alelles. Between September 2009-November 2019, 74 pediatric patients with JIA (1), 62 AIH (2) and 60 controls were assessed for CD. All children with one or more positive CD antibodies were submitted to gastrointestinal endoscopy with intestinal biopsy. All patients underwent HLA molecular assessment for DQ2/DQ8 alleles. Celiac prevalence after screening was 6.7% in the first group, 6.4% in the second group and 0% among controls. The results didn�t reveal significant differences regarding the CD prevalence among patients with JIA and AIH (p = 0.94). The majority of cases associated the silent form of disease (77.7). DQ2/DQ8 haplotypes were found in all CD cases. Of 69 children with JIA and no CD, three (4.3%) had DQ2 haplotype. Of 58 patients with AIH and no CD, 37 children (63.8%) presented DQ2/DQ8. According to the high prevalence obtained in this study, JIA and AIH are good parameters for stratification of asymptomatic cases in order to perform CD serologic screening. The absence of DQ2 or DQ8 haplotypes will make CD diagnosis unlikely and no further tests will be required.

Sign in / Sign up

Export Citation Format

Share Document